Novel clinical trial designs emerging from the molecular reclassification of cancer
CA: A Cancer Journal for Clinicians · 2025-06 · 75 (3) · 243-267
DOI: 10.3322/caac.21880 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 22.01.2025. Verfasst von Mina Nikanjam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic, Research Design. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease, rather than the tissue of origin, that mostly drives outcomes. Consequently, oncology clinical trials have evolved from standard phase 1, 2, and 3 tissue‐specific studies; to tissue‐specific, biomarker‐driven trials; to tissue‐agnostic trials untethered from histology (all drug‐centered designs ); and, ultimately, to patient‐centered , N‐of‐1 precision medicine studies in which each patient receives a personalized, biomarker‐matched therapy/combination of drugs. Innovative technologies beyond genomics, including those that address transcriptomics, immunomics, proteomics, functional impact, epigenetic changes, and metabolomics, are enabling further refinement and customization of therapy. Decentralized studies have the potential to improve access to trials and precision medicine approaches for underserved minorities. Evaluation of real‐world data, assessment of patient‐reported outcomes, use of registry protocols, interrogation of exceptional responders, and exploitation of synthetic arms have all contributed to personalized therapeutic approaches. With greater than 1 × 10 12 potential patterns of genomic alterations and greater than 4.5 million possible three‐drug combinations, the deployment of artificial intelligence/machine learning may be necessary for the optimization of individual therapy and, in the near future, also may permit the discovery of new treatments in real time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA.
- Moores Cancer Center, University of California San Diego Health, La Jolla, California, USA.
- Patient Author, San Diego, California, USA.
- Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, California, USA.
- Department of Pharmacology, University of California San Diego, San Diego, California, USA.
- Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
ORCID-Profile: Mina Nikanjam, Jason K Sicklick
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Nikanjam, M., Kato, S., Allen, T., Sicklick, J. K., & Kurzrock, R. (2025). Novel clinical trial designs emerging from the molecular reclassification of cancer. CA: A Cancer Journal for Clinicians, 75(3), 243-267. https://doi.org/10.3322/caac.21880
Vancouver
Nikanjam M, Kato S, Allen T, Sicklick JK, Kurzrock R. Novel clinical trial designs emerging from the molecular reclassification of cancer. CA: A Cancer Journal for Clinicians. 2025;75(3):243-267. doi:10.3322/caac.21880
BibTeX
@article{Nikanjam2025,
author = {Nikanjam, Mina and Kato, Shumei and Allen, Teresa and Sicklick, Jason K and Kurzrock, Razelle},
title = {Novel clinical trial designs emerging from the molecular reclassification of cancer},
journal = {CA: A Cancer Journal for Clinicians},
year = {2025},
volume = {75},
number = {3},
pages = {243--267},
doi = {10.3322/caac.21880}
}
EUVIMED